People with diabetes and a foot ulcer carry a dual burden: a threatened limb and a high risk of cardiovascular events. Roughly half of those with a diabetic foot ulcer also have peripheral artery disease (PAD), which raises the risk of both adverse limb outcomes and cardiovascular death (Fitridge et al., 2023). Because atherosclerosis drives both problems, cholesterol-lowering therapy has become a topic of interest in limb preservation. This article reviews what the evidence says about statins and other lipid-lowering agents in diabetic foot disease, and where the evidence is still limited.
Statins and Amputation Risk in Diabetes with PAD
The strongest signals for limb benefit come from observational data. In a nationwide Taiwanese cohort of 69,332 patients with type 2 diabetes and PAD, Hsu and colleagues (2017) compared statin users (n = 11,409) with patients who never received lipid-lowering drugs (n = 53,493). Statin use was associated with a lower risk of lower-extremity amputation (adjusted hazard ratio 0.75; 95% CI 0.62–0.90), cardiovascular death (aHR 0.78) and all-cause mortality (aHR 0.73). The association persisted in a propensity-matched analysis that accounted for the competing risk of death (amputation HR 0.77; 95% CI 0.61–0.97).
These findings are consistent with the 2024 multisociety guideline, which recommends high-intensity statin therapy for all patients with lower extremity PAD, aiming for at least a 50% reduction in LDL cholesterol (Class 1, Level of Evidence A) (Gornik et al., 2024). An important caveat applies: observational studies show association rather than causation, and patients who receive statins may differ from those who do not in ways that are difficult to measure.
Statins and Ulcer Healing: Limited and Mixed Evidence
Although statins have anti-inflammatory and endothelial effects that might theoretically support wound repair, clinical evidence for a direct healing benefit is weak. In a retrospective case–control series of 109 adults with an active diabetic foot ulcer, O’Dell and colleagues (2024) found that 48.0% of statin users healed within 12 weeks compared with 44.1% of non-users, a difference that was not statistically significant (p = 0.7). Prior minor amputation was the factor most clearly associated with poorer healing. The authors noted that statin dose was not recorded and called for prospective, dose-specific studies. At present, statins are best understood as protecting the vascular system and the patient’s overall cardiovascular prognosis, rather than as an established wound-healing therapy.
Going Beyond Statins: PCSK9 Inhibition and Limb Events
For patients who remain above LDL targets on a maximally tolerated statin, additional agents may help. The FOURIER trial of the PCSK9 inhibitor evolocumab included 3,642 participants with symptomatic lower-extremity PAD. In the PAD subgroup, evolocumab produced an absolute risk reduction of 3.5% in the primary cardiovascular endpoint over a median of 2.5 years, compared with 1.4% in patients without PAD (Bonaca et al., 2018). Across the trial, evolocumab also reduced major adverse limb events (HR 0.58; 95% CI 0.38–0.88). The 2024 guideline considers it reasonable to add a PCSK9 inhibitor and/or ezetimibe when LDL cholesterol remains at or above 70 mg/dL on maximally tolerated statin therapy (Class 2A) (Gornik et al., 2024). The same guideline supports GLP-1 receptor agonists and SGLT2 inhibitors for reducing major cardiovascular events in people with PAD and type 2 diabetes.
Where Lipid Management Fits in Limb Care
The intersocietal IWGDF, ESVS and SVS guidelines emphasize that PAD in people with diabetes and a foot ulcer is common and consequential, and that comprehensive management extends beyond revascularization decisions (Fitridge et al., 2023). Lipid control is one component of that systemic approach, alongside glycemic management, blood pressure control, smoking cessation, and antithrombotic therapy. Statin therapy is also frequently under-prescribed in patients with PAD, which represents a practical gap between guideline recommendations and care delivery.
Key Takeaways
High-intensity statin therapy is guideline-recommended in lower extremity PAD and is associated, in observational data, with fewer amputations and lower cardiovascular mortality in people with diabetes. Evidence that statins accelerate ulcer healing is limited and inconclusive. For patients with persistently elevated LDL cholesterol, PCSK9 inhibitors have reduced both cardiovascular and limb events in a large randomized trial. Randomized evidence specific to diabetic foot ulcers remains a research priority.
References
- Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial. Circulation. 2018.
- Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. Journal of Vascular Surgery. 2023;78(5):1101–1131.
- Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/multisociety guideline for the management of lower extremity peripheral artery disease. Journal of the American College of Cardiology. 2024.
- Hsu CY, Chen YT, Su YW, et al. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. Journal of Clinical Endocrinology and Metabolism. 2017;102(7):2373–2381.
- O’Dell B, Rothenberg G, Holmes C, et al. The impact of statin therapy on the healing of diabetic foot ulcers: a case–control series. Clinical Diabetes and Endocrinology. 2024;10:19.
Comments
